Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of [preventing] prophylactically or therapeutically treating Alzheimer's disease [an amyloidogenic disease in a patient], comprising administering to the patient an effective dosage of an antibody that specifically binds to an epitope within residues 1-12 of Aβ [binds to a component of an amyloid deposit in the patient], wherein the isotype of the antibody is human IgG1, and thereby prophylactically or therapeutically treating the patient.

2-4. Cancel

5. (Original) The method of claim 1, wherein the patient is human.

6. Cancel

7. (Original) The method of claim 1, wherein the patient is asymptomatic.

8. (Original) The method of claim 1, wherein the patient is under 50.

9. (Original) The method of claim 1, wherein the patient has inherited risk factors indicating susceptibility to Alzheimer's disease.

10. (Original) The method of claim 1, wherein the patient has no known risk factors for Alzheimer's disease.

11. (Original) The method of claim 1, wherein the antibody is a human antibody.

12. (Original) The method of claim 1, wherein the antibody is a humanized antibody.

13. (Canceled)

14. (Original) The method of claim 1, wherein the antibody is a polyclonal antibody.

15. (Original) The method of claim 1, wherein the antibody is a monoclonal antibody.

16-18. (Canceled)

19. (Original) The method of claim 1, wherein the antibody comprises two pairs of light and heavy chains.

20. (Original) The method of claim 1, wherein the dosage of antibody is 0.01 to 5 mg/kg body weight of the patient.

21. (Original) The method of claim 1, wherein the antibody is administered with a carrier as a pharmaceutical composition.

22. (Original) The method of claim 1, wherein the antibody specifically binds to Aβ peptide without binding to full-length amyloid precursor protein (APP).

23. (Original) The method of claim 1, wherein the antibody is administered intraperitoneally, orally, intranasally, subcutaneously, intramuscularly, topically or intravenously.

24. (Withdrawn) The method of claim 1, wherein the antibody is administered by administering a polynucleotide encoding at least one antibody chain to the patient, wherein the polynucleotide is expressed to produce the antibody chain in the patient.

25. (Withdrawn) The method of claim 24, wherein the polynucleotide encodes heavy and light chains of the antibody, which polynucleotide is expressed to produce the heavy and light chains in the patient.

26. (Original) The method of claim 1, further comprising monitoring the patient for level of administered antibody in the blood of the patient.

27. (Withdrawn) A pharmaceutical composition comprising an antibody that specifically binds to a component of an amyloid deposit and a pharmaceutical carrier.

28. (Withdrawn) The pharmaceutical composition of claim 27, wherein the antibody is a human or humanized antibody.

29. (Withdrawn) The pharmaceutical composition of claim 27 or 28, wherein the antibody specifically binds to Aβ.

30. (Withdrawn) The pharmaceutical composition of claim 29, wherein the antibody specifically binds to an epitope within residues 1-12 of Aβ.

31. (New) The method of claim 1, wherein the antibody is a chimeric antibody.

32. (New) The method of claim 1, wherein the patient has the disease.

33. (New) the method of claim 1, wherein the antibody is administered as a pharmaceutical composition comprising the antibody.

34. (New) The method of claim 1, further comprising administering a further dosage of antibody when the level of the antibody has declined below a reference level of the antibody in the patient.

35. (New) The method of claim 33, wherein a single dosage of the antibody is administered on multiple occasions.

36. (New) The method of claim 35, wherein the single dosage is administered once every week, once per every two weeks, once a month, once every 3 to 6 months, or yearly.

37. (New) The method of claim 35, wherein the multiple occasions occur at irregular intervals, and the method further comprises measuring blood levels of antibodies to Aβ to determine the intervals.

38. (New) The method of claim 35, further comprising administering a further dosage of antibody when the level of the antibody has declined below a predetermined percentage of a peak less baseline or a reference level of the antibody in the patient.

39. (New) The method of claim 1, wherein the method further comprises monitoring a response to the administration of the antibody in the patient.

40. (New) The method of claim 35, wherein the antibody is administered as a pharmaceutical composition comprising the antibody.